Dr David Powell

David serves as Chief Scientific Officer at Summit Therapeutics. He joined Summit as head of preclinical research in 2017 following a 20 plus year career in GSK. David’s previous role was Director and Head of the Crick-GSK Biomedical LinkLabs, based at GSK’s UK R&D hub at Stevenage, UK, and The Francis Crick Institute in London.,David combines a wide array of biology expertise with a wealth of drug discovery experience across different therapeutic areas: Neurosciences, Cardiovascular, Immuno-Inflammation and Anti-Infectives. David has a keen interest in collaborations with academia, leading GSK’s flagship collaboration with the Francis Crick Institute in London while working as part of GSK’s Discovery Partnerships with Academia team. ,Leading preclinical discovery since joining Summit, David is leading the company’s efforts to discover new mechanism antibiotics, as well as leading the scientific program on Summit's Phase 3 antibiotic, ridinilazole. David is based in Cambridge, UK, where Summit’s preclinical research continues following the acquisition of Discuva in 2017.,David was awarded a BSc (Microbiology) and MSc (Biotechnology) from the National University of Ireland Galway, before completing a PhD on retroviral proteases at Cardiff University,